RxDoctor Payments Data

Lehman Godwin, MD

Internal Medicine · Springfield, MONPI 1851339303

Payments from drug & device makers

$2,380in general payments, 2019–2025

Across 172 payments — averaging $13.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$309
  • AbbVie$294
  • Boehringer Ingelheim$201
  • AstraZeneca$198
  • Amgen$190
  • Novo Nordisk$152
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,30997%
  • Education$713%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,380 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$183,915
Medicare patients
450
Services billed
5,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$260,353
OzempicSemaglutide84$106,514
XifaxanRifaximin12$42,136
JardianceEmpagliflozin37$37,495
EntrestoSacubitril/Valsartan40$36,017
FarxigaDapagliflozin Propanediol20$28,873
XareltoRivaroxaban42$28,642
TrulicityDulaglutide25$23,228
Repatha SureclickEvolocumab14$22,277
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$20,905
Bydureon BciseExenatide Microspheres16$18,687
AbrysvoRsv Vacc, Pref A And Pref B/Pf56$17,079
InvokanaCanagliflozin19$16,651
Spiriva RespimatTiotropium Bromide26$16,178
MyrbetriqMirabegron16$14,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$309$277,432331 claims
Novo NordiskOzempic$152$106,51484 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat$201$72,47799 claims
Johnson & JohnsonXarelto, Invokana$100$45,29461 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$28$42,13612 claims
AstraZenecaFarxiga, Symbicort$198$36,37051 claims
NovartisEntresto$84$36,01740 claims
Lilly USA, LLCTrulicity$134$23,22825 claims
Astellas Pharma US IncMyrbetriq$74$14,95116 claims
AbbVieLinzess$294$8,31515 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$138$5,75811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →